A 78-YEAR-OLD MAN with multiple medical comorbidities, including coronary artery disease, hypertension, and peripheral vascular disease, underwent aortobifemoral bypass grafting and concomitant femoral-popliteal bypass for short-distance buttock and thigh claudication. An arteriogram performed preoperatively demonstrated severe aortoiliac occlusive disease. He had been on long-term warfarin therapy since the 1960s for an unknown hypercoagulable state and recurrent episodes of deep venous thromboses.

The operation proceeded unremarkably; however, by postoperative day 6, the patient was noted to have necrosis of the tips of his fingers on both hands, the right being worse (Figure 1). He had been given intravenous heparin on postoperative day 2 due to his history of hypercoagulability. His presurgery platelet count was $205 \times 10^3/\mu L$. His platelet count postoperatively dropped to $81 \times 10^3/\mu L$. This decrease was felt to be due to operative dilution and blood loss. However, by the sixth postprocedure day, the platelet count had dropped further to $50 \times 10^3/\mu L$.

What Is the Most Appropriate Treatment for This Patient?

A. Obtain PF4-heparin antibody enzyme-linked immunosorbent assay results
B. Stop all heparin therapy and treat with lepirudin
C. Amputate all necrotic digits
D. Transfuse with platelets until level is within normal range

*From the Joseph B. Whitehead Department of Surgery, Division of Vascular Surgery, Emory University School of Medicine and the Emory University Hospital, Atlanta, Ga.*

**Figure 1.**
Heparin was originally discovered in 1916 from liver extracts. Now it is more commonly prepared from either bovine or porcine mucosal extracts. The mechanism of action is via binding to antithrombin III, which then inactivates the activated coagulation factors IIa, IXa, and Xa (Figure 2). Heparin-induced thrombocytopenia (HIT) occurs in up to 6% of patients receiving heparin therapy for any reason. There are 2 types of HIT that occur clinically. Type I, which is more asymptomatic and this type is rarely associated with thromboembolic sequelae. Conversely, type II is delayed in onset and is more severe. Thromboembolic complications do occur with type II.

In type II HIT, an immune-mediated platelet aggregation caused by IgG and IgM binding to platelet factor 4 complex occurs. Platelet activation by antiheparin platelet factor 4 antibodies results, with subsequent release of thrombogenic particles. This may lead to the “white clot” syndrome, associated with limb- and/or life-threatening thromboembolic complications. Risk factors for HIT include history of unfractionated heparin exposure, intravenous fractionated heparin, bovine heparin, and cardiopulmonary bypass.

The clinical diagnosis of HIT is made when a patient’s platelet count decreases below 1500 × 10^9/µL or 30% to 50% from baseline, an effect that is seen at least 5 days following heparin exposure. Appropriate confirming laboratory data may include platelet counts, PF4-heparin antibody levels by enzyme-linked immunosorbent assay, heparin-induced platelet aggregation, and serotonin release assay. The management of HIT involves the discontinuation of all heparin, including flushes and heparin-coated catheters. The patient must then be treated against further thrombotic episodes with a direct thrombin inhibitor, such as lepirudin. This is an intravenous medication, which is monitored by maintaining the partial thromboplastin time 2 to 3 times above the baseline level. Hirudin was originally isolated from the salivary glands of the medicinal leech. It is now produced as lepirudin (r-hirudin) by recombinant DNA technology.

Corresponding author: Peter H. Lin, MD, The Emory Clinic, 1365 A Clifton Rd NE, Suite 3323, Atlanta, GA 30322 (e-mail: peter_lin@emory.org).

REFERENCES